SLC5A2 and hydrops fetalis: Third, new HF treatments have been routinely implemented in routine HF practice after the study period, such as the angiotensin receptor/neprilysin inhibitor (ARNi) and the sodium‐glucose cotransporter‐2 (SGLT2) inhibitors; this dataset included most guideline‐recommended treatments, namely, those that were used at the time of the study.8